October 7, 2016
(STAT News) – Immunotherapy, which harnesses the body’s immune system to attack tumors, brings with it the hope of significant remission, if not a cure, for some patients. But clinical trials often exclude those who have already had similar treatments, in part because researchers are seeking clear indications of a particular drug’s effectiveness. For patients, that means the stakes on a single decision couldn’t be higher. And many have little data on the drugs to guide them.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.